From London: Cancer Research Horizons takes research from Cancer Research UK (and beyond) and invests in the translational work and companies that turn it into cures
CEO Iain Foulkes describes the impact Cancer Research Horizons has already made (14 marketed medicines), which has allowed more than £600M in royalty income to be reinvested in research. He describes the structure of the organization, a new startup fund, and some notable investments.
2 days ago
This biotech CEO believes that GLP-1s will eventually be replaced by a different class of medicines as the go-to weight loss drugs
Zealand's Adam Steensberg makes the case for Amylins Coverage brought to you by
6 days ago
Jefferies London: Ipsen has done a string of deals over recent years, including acquiring ImCheck last month. CEO David Loew says the company has billions in firepower to do more
He also goes over the company's programs in aesthetics, liver disease, and oncology. Coverage brought to you by
Nov 19
.png){kind=logo}
